Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ENO1 | P06733 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020675 | 0.83 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL13531163 | 0.78 | PRKCA (0.39) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL681950 | 0.77 | PRKCA (0.46) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL13349186 | 0.75 | PRKCA (0.44) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL10253729 | 0.74 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL27999368 | 0.72 | PRKCA (0.43) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL5534787 | 0.72 | PRKCA (0.43) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL390512 | 0.71 | PRKCA (0.39) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL6840505 | 0.71 | PRKCA (0.40) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL19235874 | 0.71 | PRKCA (0.40) | PRKCABTN3A1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | PRKCA 3887/4885BTN3A1 4836/4885ALDH1A1 2219/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | PRKCA 3887/4885BTN3A1 4836/4885ALDH1A1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.